Objective: This study aims to determine the disease-free survival and overall survival outcome of patients with IB to IIA cervical cancer managed with surgery, chemoradiation, or a combination of both in a tertiary government training hospital. Methodology: This is a retrospective study of patients diagnosed with stage IB-IIA2 cervical cancer from January 2013 to June 2017. Data were encoded using Microsoft Excel. Statistical analyses were computed using SPSS. Cox regression and Kaplan Meier analyses were used to predict survival outcomes. Results: Out of 135 patients were included in the study, 111 received treatment. 61 had no evidence of disease. Median age is 46 years with stage IB1 disease. Majority of patients underwent surgery followed by adjuvant therapy. Tumor recurrence was highest in the surgery alone group, with median time to recurrence of 19 months. Median follow-up time was 10 months. Overall 5-year survival is 51.4%; 5-year disease-free survival is 54.8%. Conclusions Age is a statistically significant factor in survival. Surgery with adjuvant chemotherapy + radiation had the most favorable survival outcome. Neoadjuvant treatment gave the least number of recurrences. Despite a small sample size, this study provides baseline data into the survival outcome of patients with locally advanced cervical cancer in our institution given the different treatment recommendations.
Uterine Cervical Neoplasms ; Disease-Free Survival ; Hysterectomy ; Chemotherapy, Adjuvant ; Neoadjuvant Therapy

Purpose: Nocturia significantly impacts patients’ quality of life but remains insufficiently evaluated and treated. The “Sleep C.A.L.M.” system categorizes the factors thought to collectively reflect most underlying causes of nocturia (Sleep disorders, Comorbidities, Actions [i.e., modifiable patient behaviors such as excess fluid intake], Lower urinary tract dysfunction, and Medications). The purpose of this study was to assess the association of nocturia with the Sleep C.A.L.M. categories using a nationally representative dataset. Methods: Retrospective analysis of the National Health and Nutrition Examination Survey from 2013/14–2017/18 cycles was conducted. Pertinent questionnaire, laboratory, dietary, and physical examination data were used to ascertain the presence of Sleep C.A.L.M. categories in adults ≥20 years of age. Nocturia was defined as ≥2 nighttime voids. Results: A total of 12,274 included subjects were included (51.6% female; median age, 49.0 years [interquartile range, 34.0–62.0 years]; 27.6% nocturia). Among subjects with nocturia, the prevalence of 0, ≥1, and ≥2 Sleep C.A.L.M. categories was 3.5% (95% confidence interval [CI], 2.8%–4.4%), 96.5% (95% CI, 95.6%–97.2%), and 81.2% (95% CI, 78.9%–83.3%), respectively. Compared to those with 0–1 Sleep C.A.L.M. categories, the adjusted odds of nocturia in subjects with 2, 3, and 4–5 Sleep C. A.L.M. categories were 1.77 (95% CI, 1.43–2.21), 2.33 (1.89–2.87), and 3.49 (2.81–4.35), respectively (P<0.001). Similar trends were observed for most age and sex subgroups. When assessed individually, each of the 5 Sleep C.A.L.M. categories were independently associated with greater odds of nocturia, which likewise persisted across multiple age and sex subgroups. Conclusions Sleep C.A.L.M. burden is associated with increased odds of nocturia in a dose-dependent fashion, and potentially a relevant means by which to organize the underlying etiologies for nocturia among community-dwelling adults.